XML 129 R101.htm IDEA: XBRL DOCUMENT
v3.23.3

Other Liabilities - Contingent Consideration - Business Combination (Details) - USD ($) $ in Millions | Jun. 30, 2023 | Jun. 30, 2022 | Feb. 29, 2020
--- | --- | --- | ---
Business Acquisition [Line Items] |  |  |
Contingent consideration | $ 0.0 | $ 0.4 |
Innovus Pharmaceuticals, Inc |  |  |
Business Acquisition [Line Items] |  |  |
Business combination, contingent consideration, product related, milestone payable, amount |  |  | $ 0.2
Business combination, contingent consideration, product related, milestone payable, discount rate (as a percent) |  |  | 30.00%

X
- Definition Business Combination, Contingent Consideration, Product Related, Milestone Payable, Amount + References No definition available. + Details
Name: | aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableAmount
Namespace Prefix: | aytu_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Contingent Consideration, Product Related, Milestone Payable, Discount Rate + References No definition available. + Details
Name: | aytu_BusinessCombinationContingentConsiderationProductRelatedMilestonePayableDiscountRate
Namespace Prefix: | aytu_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=aytu_InnovusPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |